LABA/ICS Combination (e.g., Fluticasone/Salmeterol)
Treatment for Copd
Typical Dosage: Fluticasone 250 mcg/Salmeterol 50 mcg twice daily
Effectiveness
75%
Safety Score
50%
Clinical Trials
1
Participants
60K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
50
DangerousModerateSafe
Treatment Details
Dosage Range
Fluticasone 250 mcg/Salmeterol 50 mcg twice daily
Time to Effect
15-30 minutes (bronchodilation), weeks-months (exacerbation reduction)
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
10(Treat 10 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$3,600
Monitoring:$800
Side Effect Mgmt:$150
Total Annual:$4,550
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$45,000/QALY
QALYs Gained
0.03
Outcome-Based Costs
Cost per Responder
$7,583
Comparison vs Salmeterol (LABA monotherapy)
Cost Difference
+$300/year
More expensive
QALY Difference
+0.03 QALYs
Better outcomes
Dominance
No dominance
LABA/ICS Combination (e.g., Fluticasone/Salmeterol) Outcomes
for Copd
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+60%
Common Side Effects
Nasopharyngitis
+15%
Headache
+12%
Oral candidiasis
+10%
Pneumonia
+6%
Bronchitis
+5%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
1 completed trial for LABA/ICS Combination (e.g., Fluticasone/Salmeterol) in Copd
WEUSKOP6416: Evaluating Pneumonia in Chronic Obstructive Pulmonary Disease (COPD) Subjects
NCT01763463COMPLETED
1 participants
OBSERVATIONAL
Started: Jul 1, 2012